A slew of oncology stakeholders have offered the US FDA's Oncology Center of Excellence (OCE) a series of niche recommendations for improvement. OCE officials have sat and listened, which now shifts the question to who will get what they want.
In a March 15 OCE listening session, advocates and industry representatives gave their wish lists to OCE with regard to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?